All > Metastatic Lung Cancer > Lung Cancer

RO5126766 for Non-small Cell Lung Cancer

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Non-small Cell Lung CancerRO5126766 - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing a new drug for people with lung cancer who have already tried other treatments. The goal is to see if it is safe and if it has any effect on the cancer.

Eligible Conditions
  • Non-small Cell Lung Cancer

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
Rigosertib Sodium
1
Estradiol
1
OpenBiome FMT product FMP250

Study Objectives

2 Primary · 0 Secondary · Reporting Duration: 1 year

1 year
The maximum tolerated dose (MTD)
overall response rate (dose expansion)

Trial Safety

Safety Progress

1 of 3

Similar Trials

1
Rigosertib Sodium
1
Estradiol
1
OpenBiome FMT product FMP250

Trial Design

1 Treatment Group

RO5126766 (CH5126766)
1 of 1

Experimental Treatment

15 Total Participants · 1 Treatment Group

Primary Treatment: RO5126766 · No Placebo Group · Phase 1

RO5126766 (CH5126766)
Drug
Experimental Group · 1 Intervention: RO5126766 · Intervention Types: Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
RO-5126766 free base
Not yet FDA approved

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 1 year

Who is running the clinical trial?

Chugai Pharma USAIndustry Sponsor
8 Previous Clinical Trials
4,624 Total Patients Enrolled
Dana-Farber Cancer InstituteOTHER
1,016 Previous Clinical Trials
393,783 Total Patients Enrolled
9 Trials studying Non-small Cell Lung Cancer
460 Patients Enrolled for Non-small Cell Lung Cancer
Memorial Sloan Kettering Cancer CenterLead Sponsor
1,832 Previous Clinical Trials
584,523 Total Patients Enrolled
10 Trials studying Non-small Cell Lung Cancer
373 Patients Enrolled for Non-small Cell Lung Cancer
Gregory Riely, MD, PhDPrincipal InvestigatorMemorial Sloan Kettering Cancer Center
2 Previous Clinical Trials
47 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have not received a PD-1/L1 inhibitor for treatment of your disease
You have previously received chemotherapy.
Measurable and/or evaluable disease (RECIST 1.1) indicator lesion not previously irradiated.
You have a total bilirubin level of less than 1.
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top